fda warning glp-1 october 2025 Medscape | The has approved once-daily oral semaglutide 25 mg (Wegovy Pill, Novo Nordisk) as the first agonist pill for weight management. ⁠ Expert Opinion - The Undisclosed

Notably, individuals with severe kidney disease should refrain from using the medication unless specifically instructed by a physician

55M people globally are affected by dementia, with 70% of that population having Alzheimers disease, which is characterized by the buildup of two proteins in the brain, amyloid and tau

(Baltimore) 102, e33233

Weight Loss, Mobility, and What to Expect Joint pain, stiffness, and limited mobility are common concerns among adults living with obesity

Weight-based dosing challenges, accelerated drug clearance, and adipose-driven immune activation all conspire to undermine therapeutic response